A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19
- PMID: 33982445
- PMCID: PMC8239543
- DOI: 10.1111/cts.13052
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19
Abstract
Camostat mesylate, an oral serine protease inhibitor, is used to treat chronic pancreatitis and reflux esophagitis. Recently, camostat mesylate and its active metabolite 4-(4-guanidinobenzoyloxy)phenylacetic acid (GBPA) were reported to inhibit the infection of cells by severe acute respiratory syndrome coronavirus 2 by inhibiting type II transmembrane serine protease. We conducted a phase I study to investigate high-dose camostat mesylate as a treatment for coronavirus disease 2019. Camostat mesylate was orally administered to healthy adults at 600 mg 4 times daily under either of the following conditions: fasted state, after a meal, 30 min before a meal, or 1 h before a meal, and the pharmacokinetics and safety profiles were evaluated. In addition, the time of plasma GBPA concentration exceeding the effective concentration was estimated as the time above half-maximal effective concentration (EC50 ) by using pharmacokinetic/pharmacodynamic modeling and simulation. Camostat mesylate was safe and tolerated at all dosages. Compared with the fasted state, the exposure of GBPA after a meal and 30 min before a meal was significantly lower; however, no significant difference was observed at 1 h before a meal. The time above EC50 was 11.5 h when camostat mesylate 600 mg was administered 4 times daily in the fasted state or 1 h before a meal. Based on the results of this phase I study, we are currently conducting a phase III study.
© 2021 ONO Pharmaceutical Co., Ltd. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Conflict of interest statement
J.K., H.I., H.A., J.M., K.F., S.O., and S.N. are employees of Ono Pharmaceutical Co., Ltd. T.H. is a consultant and N.U. is a paid consultant of Ono Pharmaceutical Co., Ltd. All other authors declare no competing interests for this work.
Figures
References
-
- World Health Organization . Coronavirus disease (COVID‐19) Weekly Epidemiological Update and Weekly Operational Update https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019/situatio... (2020). Accessed December 9, 2020.
-
- Hoffmann M, Mösbauer K, Hofmann‐Winkler H, et al. Chloroquine does not inhibit infection of human lung cells with SARS‐CoV‐2. Nature. 2020;585:588‐590. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
